Dedifferentiated central chondrosarcoma

Eric L. Staals, Patrizia Bacchini, Franco Bertoni

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

BACKGROUND. The prognosis for patients who develop dedifferentiation of central chondrosarcoma traditionally has been poor. Because not much has been reported about this rare lesion, many uncertainties remain about prognostic factors. METHODS. In this retrospective study, the clinical, radiographic, and histologic features and the treatments in 123 patients from the Rizzoli Institute were reviewed in an attempt to define which factors may be related to outcome in patients with dedifferentiated central chondrosarcoma. RESULTS. Among 123 patients who were included in this study, 109 patients were treated at the Rizzoli Institute, and 14 patients were seen in consultation. There were 66 males and 57 females, and their average age was 59 years. The femur (62 patients), pelvis (28 patients), and humerus (20 patients) were the most common locations. Radiographically, a soft tissue mass was present in 87% of patients, and a bimorphic pattern was appreciated in 53% of patients. Histologically, the cartilaginous component was considered Grade 1 in 63% of patients and Grade 2 in 37% of patients. In most patients, the dedifferentiated component showed the features of an osteosarcoma (92 patients), followed by fibrosarcoma (19 patients), and malignant fibrous histiocytoma (9 patients). For 101 patients, surgery was a component of their definitive management. In 25 patients, surgery was combined with chemotherapy. The 2-year and 5-year survival rates were 34% and 24%, respectively. The median survival was 13 months (95% confidence interval, 9-17 months). CONCLUSIONS. Metastatic disease at diagnosis, malignant fibrous histiocytoma dedifferentiation, and a high percentage of dedifferentiated component were related to poorer outcomes. There was no statistical evidence of any beneficial effect from adjuvant chemotherapy.

Original languageEnglish
Pages (from-to)2682-2691
Number of pages10
JournalCancer
Volume106
Issue number12
DOIs
Publication statusPublished - Jun 15 2006

Fingerprint

Chondrosarcoma
Malignant Fibrous Histiocytoma

Keywords

  • Central chondrosarcoma
  • Chemotherapy
  • Dedifferentiated chondrosarcoma
  • Outcome
  • Prognostic factors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Staals, E. L., Bacchini, P., & Bertoni, F. (2006). Dedifferentiated central chondrosarcoma. Cancer, 106(12), 2682-2691. https://doi.org/10.1002/cncr.21936

Dedifferentiated central chondrosarcoma. / Staals, Eric L.; Bacchini, Patrizia; Bertoni, Franco.

In: Cancer, Vol. 106, No. 12, 15.06.2006, p. 2682-2691.

Research output: Contribution to journalArticle

Staals, EL, Bacchini, P & Bertoni, F 2006, 'Dedifferentiated central chondrosarcoma', Cancer, vol. 106, no. 12, pp. 2682-2691. https://doi.org/10.1002/cncr.21936
Staals EL, Bacchini P, Bertoni F. Dedifferentiated central chondrosarcoma. Cancer. 2006 Jun 15;106(12):2682-2691. https://doi.org/10.1002/cncr.21936
Staals, Eric L. ; Bacchini, Patrizia ; Bertoni, Franco. / Dedifferentiated central chondrosarcoma. In: Cancer. 2006 ; Vol. 106, No. 12. pp. 2682-2691.
@article{b807a82357c9433d8fae538f1ab0d36f,
title = "Dedifferentiated central chondrosarcoma",
abstract = "BACKGROUND. The prognosis for patients who develop dedifferentiation of central chondrosarcoma traditionally has been poor. Because not much has been reported about this rare lesion, many uncertainties remain about prognostic factors. METHODS. In this retrospective study, the clinical, radiographic, and histologic features and the treatments in 123 patients from the Rizzoli Institute were reviewed in an attempt to define which factors may be related to outcome in patients with dedifferentiated central chondrosarcoma. RESULTS. Among 123 patients who were included in this study, 109 patients were treated at the Rizzoli Institute, and 14 patients were seen in consultation. There were 66 males and 57 females, and their average age was 59 years. The femur (62 patients), pelvis (28 patients), and humerus (20 patients) were the most common locations. Radiographically, a soft tissue mass was present in 87{\%} of patients, and a bimorphic pattern was appreciated in 53{\%} of patients. Histologically, the cartilaginous component was considered Grade 1 in 63{\%} of patients and Grade 2 in 37{\%} of patients. In most patients, the dedifferentiated component showed the features of an osteosarcoma (92 patients), followed by fibrosarcoma (19 patients), and malignant fibrous histiocytoma (9 patients). For 101 patients, surgery was a component of their definitive management. In 25 patients, surgery was combined with chemotherapy. The 2-year and 5-year survival rates were 34{\%} and 24{\%}, respectively. The median survival was 13 months (95{\%} confidence interval, 9-17 months). CONCLUSIONS. Metastatic disease at diagnosis, malignant fibrous histiocytoma dedifferentiation, and a high percentage of dedifferentiated component were related to poorer outcomes. There was no statistical evidence of any beneficial effect from adjuvant chemotherapy.",
keywords = "Central chondrosarcoma, Chemotherapy, Dedifferentiated chondrosarcoma, Outcome, Prognostic factors",
author = "Staals, {Eric L.} and Patrizia Bacchini and Franco Bertoni",
year = "2006",
month = "6",
day = "15",
doi = "10.1002/cncr.21936",
language = "English",
volume = "106",
pages = "2682--2691",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Dedifferentiated central chondrosarcoma

AU - Staals, Eric L.

AU - Bacchini, Patrizia

AU - Bertoni, Franco

PY - 2006/6/15

Y1 - 2006/6/15

N2 - BACKGROUND. The prognosis for patients who develop dedifferentiation of central chondrosarcoma traditionally has been poor. Because not much has been reported about this rare lesion, many uncertainties remain about prognostic factors. METHODS. In this retrospective study, the clinical, radiographic, and histologic features and the treatments in 123 patients from the Rizzoli Institute were reviewed in an attempt to define which factors may be related to outcome in patients with dedifferentiated central chondrosarcoma. RESULTS. Among 123 patients who were included in this study, 109 patients were treated at the Rizzoli Institute, and 14 patients were seen in consultation. There were 66 males and 57 females, and their average age was 59 years. The femur (62 patients), pelvis (28 patients), and humerus (20 patients) were the most common locations. Radiographically, a soft tissue mass was present in 87% of patients, and a bimorphic pattern was appreciated in 53% of patients. Histologically, the cartilaginous component was considered Grade 1 in 63% of patients and Grade 2 in 37% of patients. In most patients, the dedifferentiated component showed the features of an osteosarcoma (92 patients), followed by fibrosarcoma (19 patients), and malignant fibrous histiocytoma (9 patients). For 101 patients, surgery was a component of their definitive management. In 25 patients, surgery was combined with chemotherapy. The 2-year and 5-year survival rates were 34% and 24%, respectively. The median survival was 13 months (95% confidence interval, 9-17 months). CONCLUSIONS. Metastatic disease at diagnosis, malignant fibrous histiocytoma dedifferentiation, and a high percentage of dedifferentiated component were related to poorer outcomes. There was no statistical evidence of any beneficial effect from adjuvant chemotherapy.

AB - BACKGROUND. The prognosis for patients who develop dedifferentiation of central chondrosarcoma traditionally has been poor. Because not much has been reported about this rare lesion, many uncertainties remain about prognostic factors. METHODS. In this retrospective study, the clinical, radiographic, and histologic features and the treatments in 123 patients from the Rizzoli Institute were reviewed in an attempt to define which factors may be related to outcome in patients with dedifferentiated central chondrosarcoma. RESULTS. Among 123 patients who were included in this study, 109 patients were treated at the Rizzoli Institute, and 14 patients were seen in consultation. There were 66 males and 57 females, and their average age was 59 years. The femur (62 patients), pelvis (28 patients), and humerus (20 patients) were the most common locations. Radiographically, a soft tissue mass was present in 87% of patients, and a bimorphic pattern was appreciated in 53% of patients. Histologically, the cartilaginous component was considered Grade 1 in 63% of patients and Grade 2 in 37% of patients. In most patients, the dedifferentiated component showed the features of an osteosarcoma (92 patients), followed by fibrosarcoma (19 patients), and malignant fibrous histiocytoma (9 patients). For 101 patients, surgery was a component of their definitive management. In 25 patients, surgery was combined with chemotherapy. The 2-year and 5-year survival rates were 34% and 24%, respectively. The median survival was 13 months (95% confidence interval, 9-17 months). CONCLUSIONS. Metastatic disease at diagnosis, malignant fibrous histiocytoma dedifferentiation, and a high percentage of dedifferentiated component were related to poorer outcomes. There was no statistical evidence of any beneficial effect from adjuvant chemotherapy.

KW - Central chondrosarcoma

KW - Chemotherapy

KW - Dedifferentiated chondrosarcoma

KW - Outcome

KW - Prognostic factors

UR - http://www.scopus.com/inward/record.url?scp=33745201883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745201883&partnerID=8YFLogxK

U2 - 10.1002/cncr.21936

DO - 10.1002/cncr.21936

M3 - Article

C2 - 16691621

AN - SCOPUS:33745201883

VL - 106

SP - 2682

EP - 2691

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -